News

Video

Dr Husain on Developments in ALK+ NSCLC

Author(s):

Hatim Husain, MD
Conference|International Lung Cancer Congress

Hatim Husain, MD, discusses developments in ALK-positive non–small cell lung cancer.

Hatim Husain, MD, medical oncologist and assistant professor of medicine at Moores Cancer Center of the University of California, San Diego, discusses developments in ALK-positive non–small cell lung cancer.

Related Videos
Ben Levy, MD, and Yan Leyfman, MD
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation To Address The Evolved Landscape Of EGFR Mutant NSCLC
Video 14 - "Key Takeaways in HER2-Mutated NSCLC"
Video 13 - "Treatment Considerations in HER2-Mutated NSCLC"
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Sumanta Kumar Pal, MD, FASCO,
A panel of 5 experts on lung cancer
Related Content
Raajit K. Rampal, MD, PhD
June 1st 2024

Updated MANIFEST-2 Data With Pelabresib/Ruxolitinib Support Paradigm Shift in Myelofibrosis

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Here is your guide to important regulatory approvals made by the FDA in May 2024.
May 31st 2024

OncLive’s May Roundup of Key FDA Approvals in Oncology

Hari B. Keshava, MD
October 23rd 2023

Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection

Jorge E. Cortes, MD, of Georgia Cancer Center at Augusta University
May 31st 2024

Asciminib Bests Standard-of-Care TKIs in Ph+ CML

Benjamin J. Solomon, MBBS, PhD
May 31st 2024

Lorlatinib Yields Longest Reported PFS in Advanced ALK+ NSCLC